Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

The funds will be utilised to progress the global clinical development of Allink's lead candidates, ALK201 and ALK202.

Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, today announced the successful completion ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

The successful completion of this round of financing marks a pivotal moment in AllinkBio's growth trajectory. With the new financial resources in place, combined with the company's efficient R&D ...

Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, including a drug heading for ...

Since its inception in 2021, VelaVigo has built an extensive pipeline of over ten FIC/BIC multi-specific antibodies and ADC molecules for oncology and autoimmune diseases. It has also set up VelaVigo ...

Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and ...

Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer: Nanjing, China Saturday, November 2 ...

Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and ...